Investing.com - Apellis Pharma reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Apellis Pharma announced earnings per share of $-1.75 on revenue of $17.7M. Analysts polled by Investing.com anticipated EPS of $-1.44 on revenue of $21.74M.
Apellis Pharma shares are up 6% from the beginning of the year , still down 31.97% from its 52 week high of $70.00 set on Friday, September 9, 2022.
Apellis Pharma shares gained 1.01% in after-hours trade the report.
Apellis Pharma follows other major Healthcare sector earnings this month
Apellis Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar